Yonkenafil HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529527

CAS#: 804519-64-0

Description: Yonkenafil HCl is a PDE5 inhibitor potentially for the treatment of erectile dysfunction.


Chemical Structure

img
Yonkenafil HCl
CAS# 804519-64-0

Theoretical Analysis

MedKoo Cat#: 529527
Name: Yonkenafil HCl
CAS#: 804519-64-0
Chemical Formula: C24H34ClN5O4S
Exact Mass:
Molecular Weight: 524.07
Elemental Analysis: C, 55.00; H, 6.54; Cl, 6.76; N, 13.36; O, 12.21; S, 6.12

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 804519-64-0 (HCl)   804518-63-6 (free base)  

Synonym: Yonkenafil HCl; Yonkenafil hydrochloride

IUPAC/Chemical Name: 2-(2-ethoxy-5-((4-ethylpiperazin-1-yl)sulfonyl)phenyl)-5-methyl-7-propyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one hydrochloride

InChi Key: CDCLCASCGRHUNT-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H33N5O4S.ClH/c1-5-10-28-16-17(4)21-23(28)25-22(26-24(21)30)19-15-18(8-9-20(19)33-7-3)34(31,32)29-13-11-27(6-2)12-14-29;/h8-9,15-16H,5-7,10-14H2,1-4H3,(H,25,26,30);1H

SMILES Code: O=C1C2=C(N(CCC)C=C2C)N=C(C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC)N1.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 524.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Zhao S, Yang J, Wang L, Peng S, Yin J, Jia L, Yang X, Yuan Z, Wu C. NF-κB Upregulates Type 5 Phosphodiesterase in N9 Microglial Cells: Inhibition by Sildenafil and Yonkenafil. Mol Neurobiol. 2016 May;53(4):2647-58. doi: 10.1007/s12035-015-9293-0. PubMed PMID: 26108184.

2: Sun H, Wang J, Sun Y, Peng W, Sun L, Yang Y, Gu J. Rapid and sensitive liquid chromatography with tandem mass spectrometry method for the simultaneous quantification of yonkenafil and its major metabolites in rat plasma. J Sep Sci. 2016 Oct;39(19):3700-3708. doi: 10.1002/jssc.201600445. PubMed PMID: 27601197.

3: Chen X, Wang N, Liu Y, Liu Y, Zhang T, Zhu L, Wang Y, Wu C, Yang J. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77. doi: 10.1016/j.expneurol.2014.07.007. PubMed PMID: 25064698.

4: Zhu L, Yang JY, Xue X, Dong YX, Liu Y, Miao FR, Wang YF, Xue H, Wu CF. A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model. Mech Ageing Dev. 2015 Sep;150:34-45. doi: 10.1016/j.mad.2015.07.002. PubMed PMID: 26200391.

5: Wang J, Jiang Y, Wang Y, Tang Y, Teng G, Fawcett JP, Kong J, Gu J. A rapid and sensitive LC-MS/MS assay to quantify yonkenafil in rat plasma with application to preclinical pharmacokinetics studies. J Pharm Biomed Anal. 2008 Aug 5;47(4-5):985-9. doi: 10.1016/j.jpba.2008.04.004. PubMed PMID: 18499386.

6: Jing YR, Zhou W, Li WL, Zhao LX, Wang YF. The synthesis of novel taxoids for oral administration. Bioorg Med Chem. 2014 Jan 1;22(1):194-203. doi: 10.1016/j.bmc.2013.11.037. PubMed PMID: 24332858.